Yiqing Yang

TL;DR: Although PRTOACs have been widely explored throughout the world and have outperformed not only in cancer diseases, but also in immune disorders, viral infections and neurodegenerative diseases, more efforts are needed to gain to get deeper insight into the efficacy and safety of PROTACs in the clinic.

TL;DR: This study reports the first-inclass, covalent BTK inhibitor that is able to bind C481 (Cysteine481) of BTK with an ideal IC50 of 0.5 nM, and presents the PROTAC technique as a promising alternative approach against cancer.

TL;DR: The PfNDH2 inhibitor exhibits excellent potency against both drug-resistant strains in vitro and parasite-infected mice in vivo via a potential allosteric mechanism and can be used in combination with dihydroartemisinin (DHA) synergistically.

TL;DR: A novel FAK-targeting PROTAC, FC-11, showed a rapid and reversible FAK degradation with a picomolar of DC50 in various cell lines in vitro, which imply thatFAK-PROTACs could be useful as expand tools for studying functions of FAK in biological system and as potential therapeutic agents.

TL;DR: A novel potent small molecule (RYL-634) was identified, showing excellent broad-spectrum inhibition activity against various pathogenic viruses, including hepatitis C virus, dengue virus, Zika virus, chikungunya virus, enterovirus 71, human immunodeficiency virus, respiratory syncytial virus, and others.